Nanowear Announces COVID-19 Remote Diagnostic Research Collaboration with New York City-Metro Health Systems
Jul 22, 2020, 11:00 ET
NEW YORK, July 22, 2020 /PRNewswire/ -- Nanowear www.nanowearinc.com, the leading nanotechnology-based connected-care and remote diagnostic platform, today announced an expanded COVID-19 remote diagnostic research alliance with Hackensack Meridian Health Systems, the largest hospital system in New Jersey and Maimonides Medical Center in Brooklyn, NY.
The clinical trial collaboration focuses on utilizing remote diagnostic monitoring through the use of precision medicine clinical-grade, cloth-based wearable technology. The goal is to monitor patients with confirmed or suspected COVID-19 with Nanowear's proprietary and patented cloth-based nanosensors which detect physiological and biomarker changes indicative of clinical deterioration that may require further intervention from the hospital systems.
Nanowear's digital platform enables a radical leap forward in telemedicine and remote patient diagnostics. When a patient wears SimpleSENSE, Nanowear's one-size-fits-all adjustable undergarment, physicians can remotely capture and assess multiple physiological signals – including real-time ECG, systolic and diastolic blood pressure, blood flow hemodynamics, respiration, lung volume and fluid, and temperature trends – without the need for an in-person visit or physical touch.
"When we talk about telemedicine, we often talk about video conferencing," said Venk Varadan, Co-founder and CEO. "But to truly enable remote diagnostics we must incorporate clinical-grade remote monitoring that is affordable, comfortable, and simple for patients to use. Nanowear's SimpleSENSE replaces a stethoscope, blood pressure cuff, multi-channel Holter monitor, and Capnogram (End-tidal CO2), providing a diagnostic quality monitoring system in a form factor that is easy to ship, easy to wear, and easy for the patient to use. Nanowear's garment captures 120 million data points per patient per day across cardiac, pulmonary, and circulatory biomarker data, which is transmitted to clinical staff, so that they may make informed and quicker decisions remotely."
The COVID-19 pandemic has transformed healthcare delivery and diagnosis; the traditional experience of a physician physically examining or touching a patient in-person has been altered, perhaps forever, and could have a lasting impact on the future of patient-physician physical interactions expansively from primary care to chronic disease cases.
As New York City, the epicenter of the global coronavirus pandemic, emerges from coronavirus lockdown, health systems are looking for novel technologies like Nanowear to better understand and combat the unprecedented severity of COVID-19. Nanowear is being used to aid in COVID-19 diagnosis to ensure the health and safety of patients and medical professionals.
"What we need to understand about COVID-19 is why certain patients develop a cytokine mediated immune response from the virus," said national Principal Investigator of the collaboration, Sameer Jamal, MD, of Hackensack Meridian Health, the largest health system in New Jersey. "This resulting inflammation within the circulatory system often leads to severe complications or death, which we have seen first-hand in New York City and the surrounding area. Diagnosis and co-morbidities alone is not enough to determine risk to admitted patients before they need to be transferred to ICU. Nanowear's SimpleSENSE is giving us an exponential amount of relevant data metrics about the heart and lungs from an all-in-one product that should ultimately enable us to triage lower risk patients and stratify high risk patients."
While the immediate need for hospitals across the US is to remotely diagnose and assess worsening COVID-19 instances from home-to-hospital and hospital-to-home, the virus itself has changed the paradigm for healthcare delivery in general.
"The COVID-19 paradigm shift has accelerated healthcare systems' need to implement staff-contactless monitoring involving acute and chronic disease-related hospitalizations," said John Marshall, MD, Head of Emergency Department at Maimonides Medical Center in Brooklyn, New York. "The continuity of in-patient monitoring, patient-to-home monitoring, and at-home monitoring across 8-10 biomarkers with a very easy-to-use product is what makes Nanowear's solution compelling and unique."
Unlike consumer-grade wearable garments, smartwatches, smartrings or limited-metric adhesive patches, Nanowear's textile-embedded multi-parameter nanosensors are clinical-grade, analyzing multiple cardiac, pulmonary, and circulatory biomarkers, creating a holistic personalized digital signature for each patient. The garment transmits these diagnostic health signals to a mobile application and physician portal, enabling healthcare professionals to assess a wide range of medical conditions, from diabetes, high blood pressure and congestive heart failure (CHF), to acute illness, discomfort, and stress.
"Nanowear's core of cloth-nanotechnology sensors is a differentiator from smartwatches, adhesive patches, and other medical or consumer wearables," said Suraj Kapa, MD, of Mayo Clinic. "With billions of touchpoints per centimeter and large vectors across the heart and lungs, Nanowear's skin-to-impedance barrier is lower than other wearable sensors, resulting in location-agnostic, high signal-to-noise raw data from basic skin contact. The breadth of metrics, quality and quantity of data, and comfortable user experience are key for machine learning algorithms in various diagnostic verticals, even beyond healthcare."
Nanowear's proprietary and patented cloth-based nanotechnology was invented by Co-founder and Chief Innovation Officer, Dr. Vijay Varadan and founding engineers, Dr. Pratyush Rai, Prashanth Shyam Kumar, Mouli Ramasamy and Dr. Gyanesh Mathur. SimpleSENSE achieved first-on-man status in late 2019 in the NanoSENSE Heart Failure validation study led by national Principal Investigator John Boehmer, MD, Director of Penn State Hershey Medical Center's Heart and Vascular Institute. Hackensack Meridian Health Systems and Medical University of South Carolina are also participating in the NanoSENSE Heart Failure study.
Nanowear has submitted its SimpleSENSE device and mobile platform to FDA for Class II 510(k) clearance. SimpleSENSE is not yet FDA-cleared and currently not intended to mitigate, prevent, treat, cure or diagnose any disease or condition.
About Nanowear
Nanowear is the leading developer of patented, cloth-based nanosensor technology with applications in the cardiac, neurological, industrial safety / government and sports medicine / performance diagnostics monitoring markets. The company's proprietary technology enables a closed-loop platform of wireless, real-time electrical, hemodynamic, acoustic, and metabolic monitoring that provides medical professionals with accurate, continuous diagnostics data and algorithmic alerts through a cost effective and non-invasive garment deployment. Nanowear's core focus on innovation and next-gen technologies will continue to propel the company towards exploring unique and groundbreaking applications for its nanosensors and data services. Nanowear is headquartered in New York, NY.
About Hackensack Meridian Health Systems
Hackensack Meridian Health is a leading not-for-profit healthcare organization that is the largest, most comprehensive, and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research, and life-enhancing care.
Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers. Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations.
Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The network's notable distinctions include having four hospitals among the top 10 in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker's Healthcare's "150 Top Places to Work in Healthcare/2018" list.
About Maimonides Medical Center
Maimonides Medical Center is a 711-bed non-profit tertiary care provider in Brooklyn, New York. It operates the largest hospital in Brooklyn as well as the borough's only full-service Cancer Center. Maimonides physicians are nationally known for clinical excellence, innovation and groundbreaking research. An independent teaching and research institution, Maimonides is a major clinical training site for the SUNY Downstate College of Medicine. Founded in 1911, the Medical Center continues to grow and adapt to the needs of Brooklyn's patients and families. Maimonides is an affiliate of Northwell Health. For additional information on the nationally recognized clinical services at Maimonides Medical Center, please visit www.maimonidesmed.org.
Media Contact:
Dwain Schenck
(203) 223-5230
[email protected]
SOURCE Nanowear